Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
Smoking cessation may leads to lower major adverse cardiovascular events (MACE) at 19 months to 110 months compared with continuous smoking (low certainty).
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
It is very uncertain whether chlorhexidine gluconate changes adverse events (maternal) ‐ skin irritation or allergic skin reaction compared with povidone iodine (very low certainty).
It is very uncertain whether valproate changes adverse events ‐ Sedation At 8 weeks (secondary tolerability outcome) compared with risperidone (very low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
It is very uncertain whether comparison 13: SSRIs changes dropouts due to adverse events (long term) Post‐treatment: 1‐4 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
Botulinum toxin type A probably leads to higher adverse events: sore throat/dry mouth № of participants: 212 (2 RCTs) compared with botulinum toxin type B (moderate certainty).
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
The intervention showed no clear difference in number of participants who withdraw because of adverse events (median (low certainty).
Oral or transdermal opioids leads to higher number of participants who withdrew because of adverse events (median compared with placebo (high certainty).
The review found no eligible studies for this question.